Cholestyramine Light Rx
Generic Name and Formulations:
Cholestyramine resin (as Cl) 4g; per 5g packet or scoop; contains phenylalanine.
Various generic manufacturers
Indications for Cholestyramine Light:
Hypercholesterolemia alone or with hypertriglyceridemia resistant to dietary management. Reduction in risk of coronary heart disease. Pruritus due to partial biliary obstruction.
Initially 1 packet or scoop mixed with fluid or food 1–2 times daily. Maintenance: 2–4 packets or scoops divided into 2 doses; max 6 packets or scoops daily. Increase at 4 week intervals.
See full labeling.
Complete biliary obstruction.
Obtain baseline serum cholesterol, LDL-C, and triglycerides, and monitor during therapy. May need Vit. A, D, K, and folic acid supplementation with long-term therapy. Exclude secondary causes of hypercholesterolemia (e.g., hypothyroidism, diabetes, nephrotic syndrome, dysproteinemias, obstructive liver disease, alcoholism). Favorable trend in cholesterol reduction usually occurs within 1 month; continue therapy to sustain reduction. Phenylketonuria (Light formulation). Constipation. Hemorrhoids. Pregnancy. Nursing mothers.
Bile acid sequestrant.
Inhibits absorption of phenylbutazone, warfarin, chlorothiazide, propranolol, tetracycline, penicillin G, phenobarbital, thyroid drugs, digitalis, many others; give other drugs 1–2 hours before or 4–6 hours after. Additive effects with HMG-CoA reductase inhibitors, nicotinic acid.
Constipation, fecal impaction, aggravation of hemorrhoids, GI disturbances, osteoporosis, Vit. A, D, K, or folic acid deficiencies, increased bleeding, hyperchloremic acidosis, rash, oral or anal irritation.
Formerly known under the brand name Questran Light.
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments